Morgan Stanley analyst Simeon Gutman lowered the firm's price target on Sally Beauty to $13 from $16 and keeps an Underweight rating on the shares. Sally showed "decent" execution in Q2, but the comp outlook implies a deceleration and unchanged fiscal year guidance implies a weaker earnings outlook embedded into the back-half of the year, the analyst tells investors.
